Final-Program-ATS-2023-AP.vp

338

WEDNESDAY • MAY 24

1:00 Tocilizumab Treatment Leads to Early Resolution of Myeloid Dysfunction and Lymphopenia in Patients Hospitalized With COVID-19/ R.N. Bauer, South San Francisco, CA 1:12 Cova Results From a Double-blind, Placebo-controlled Phase 2/3 Study to Assess Efficacy and Safety of BIO101 in Hospitalized Severe COVID-19 Patients/ G.B. Nair, Royal Oak, MI 1:24 Driving Pressure and Adjunctive Therapies in Pulmonary Sequelae of COVID-19 Patients Under Invasive Ventilation/ J. Gonzalez, Lleida, Spain 1:36 Evaluating the Cardiovascular Event Profile After Administration of Tixagevimab and Cilgavimab (Evusheld) in Lung Transplant Recipients/ J.L. Bulger, Maywood, IL 1:48 Evidence of Post-infection Vaccination Correlation With the Severity of Opacities and Consolidations on the Lung Parenchyma of Post-acute SARS-CoV-2 Patients/ D.S.D. Carmo, Iowa City, IA

1:12 Juvenile Regulatory T Cells Exhibit Decreased Capacity to Suppress Inflammation During Severe Viral Pneumonia/ A.D. Prigge, Chicago, IL 1:24 Protein Kinase A (PKA) Signaling Contributes to Barrier Protection Effect of Vitamin D3 Against Respiratory Syncytial Virus Infection/ N. Gao, Cleveland, OH 1:36 Respiratory Virus-specific Nasopharyngeal Lipidome Signatures and Severity in Infants Hospitalized for Bronchiolitis: A Prospective Multicenter Cohort Study/ M. Kyo, Boston, MA Featured Speaker: 1:48 New Insights into TSLP Airway Epithelial Biology During Early Life/ G.R. Nino, Washington, DC

BASIC • CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

D95

CHALLENGES AND ADVANCES IN COVID-19

BASIC • TRANSLATIONAL MINI SYMPOSIUM

12:00 p.m. - 2:00 p.m.

Walter E. Washington Convention Center Ballroom B (Level 3)

Chairing: J.P. Mizgerd, ScD, ATSF, Boston, MA M. Mehedi, PhD, Grand Forks, ND

D96

NOVEL PATHWAYS IN INFLAMMATORY LUNG INJURY

C.M. Luna, MD, PhD, Ciudad Autónoma de Buenos Aires, Argentina

12:00 p.m. - 2:00 p.m.

Walter E. Washington Convention Center Room 204 A-C (Level 2)

Oral Presentations: 12:00 COVID-19 Symptomatology in the Omicron Era: A Population-based Observational Study in Sapporo, Japan/ S. Nakakubo, Sapporo, Japan 12:12 COVI-19 Hospitalizations and Mortality in the United States, National Analysis of the Year 2020/ I. Kryshtal, Brooklyn, NY 12:24 Mitochondrial DNA Is an Early Predictor of COVID19 Severity of Disease: Validation Cohort and Response to Targeted COVID19 Treatments/ M. Cano, Saint Louis, MO 12:36 A Selective Leukotriene B4 Antagonist, Acebilustat, for Treatment of Outpatients With COVID-19 Disease: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial/ J.E. Levitt, Stanford, CA 12:48 Prior Immune Checkpoint Inhibitor Therapy in Cancer Patients Presenting With COVID-19 Was Not Associated With Worse Outcomes but Potentially Decreased COVID-19 Related Hospitalizations and Complications: Results of a Propensity-Matched Analysis Using the / A. Mostaghim, Bethesda, MD

Chairing: G.S. Budinger, MD, ATSF, Chicago, IL K. Hajipouran Benam, PhD, Pittsburgh, PA L. Morales-Nebreda, MD, Chicago, IL Featured Speaker: 12:00 Role of Osteoclasts in Silicosis/ F.X. Mccormack, Cincinnati, OH Oral Presentations: 12:12 The Role of Innate B Cells as Progenitors of the Mzb1+ Plasma Cells in Chronic Rejection After Lung Transplantation/ M. Bueno, Pittsburgh, PA 12:24 Connexin-43 Containing Gap Junctions in Sessile Alveolar Macrophages Determine Hyperinflation-induced Lung Injury/ L. Mthunzi, New York, NY 12:36 Targeting Age-dependent Nox4 Dysfunction as a Novel Strategy to Improve Survival in Age-dependent Severe ARDS/ K. Kato, Atlanta, GA 12:48 Monocyte-derived Interstitial Macrophages Stimulate Angiogenesis to Promote Lung Regeneration Following Pneumonectomy/ S. Watanabe, Kanazawa, Japan

ATS 2023 • Washington, DC